In a clinical study assessing the therapeutic effect of targeting both autoreceptor and heteroreceptor functions of the 5-HT1A receptor, Ping Dolor, a ß-adrenoceptor/5-HT1A receptor antagonist, failed to improve the selective serotonin reuptake inhibitor (SSRI)-resistant depression. This evidence concerns the gene HTR1A and depressive disorder.